RX509 Pill - white oval
Pill with imprint RX509 is White, Oval and has been identified as Amoxicillin and Clavulanate Potassium 875 mg / 125mg. It is supplied by Ranbaxy Pharmaceuticals Inc.
Amoxicillin/clavulanate is used in the treatment of Bacterial Infection; Bronchitis; Aspiration Pneumonia; Bronchiectasis; Febrile Neutropenia and belongs to the drug class beta-lactamase inhibitors. There is no proven risk in humans during pregnancy. Amoxicillin/clavulanate 875 mg / 125mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for RX509
Amoxicillin and Clavulanate Potassium
- Imprint
- RX509
- Strength
- 875 mg / 125mg
- Color
- White
- Shape
- Oval
- Availability
- Prescription only
- Drug Class
- Beta-lactamase inhibitors
- Pregnancy Category
- B - No proven risk in humans
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Ranbaxy Pharmaceuticals Inc.
- National Drug Code (NDC)
- 63304-0509 (Discontinued)
More about amoxicillin / clavulanate
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (903)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: beta-lactamase inhibitors
- En español
Patient resources
- Amoxicillin and Clavulanate drug information
- Amoxicillin and clavulanate potassium
- Amoxicillin/Clavulanate Chewable Tablets
- Amoxicillin/Clavulanate Extended-Release Tablets
- Amoxicillin/Clavulanate Tablets
- Amoxicillin/Clavulanate Suspension
Other brands
Augmentin, Augmentin ES-600, Amoclan, Augmentin XR
Professional resources
- Amoxicillin/Clavulanate monograph
- Amoxicillin and Clavulanate Chewable (FDA)
- Amoxicillin and Clavulanate ER Tablets (FDA)
- Amoxicillin and Clavulanate Oral Suspension (FDA)
- Amoxicillin and Clavulanate Tablets (FDA)
Other brands
Augmentin, Augmentin ES-600, Amoclan, Augmentin XR
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
